Recursion Pharmaceuticals Balances Early Wins and Runway

Recursion Pharmaceuticals, Inc ((RXRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Recursion Pharmaceuticals’ latest earnings call struck an optimistic tone, as management balanced fresh clinical wins with disciplined spending and growing partner support. Executives highlighted a new proof of concept in a hereditary cancer syndrome, faster drug development timelines, and a strengthened cash position, while acknowledging that key trials remain early and commercial revenues are still years away.

Clinical Proof of Concept for REC-4881 in FAP

REC-4881, an allosteric MEK1/2 inhibitor, delivered a clinical proof of concept in familial adenomatous polyposis, showing significant reductions in precancerous polyps and durable responses. Management has initiated discussions with regulators on a potential registrational path, though details on endpoints and trial design are still being worked out for this first-in-disease setting.

Early but Encouraging Profile for REC-1245

The RBM39 degrader REC-1245 posted initial Phase I data from 16 patients across four dose levels, with no dose-limiting toxicities and mainly mild to moderate gastrointestinal events. Dose-dependent exposure supports daily dosing, early pharmacodynamics confirm target engagement, and a notable share of patients were MSI-high or MMR-deficient, hinting at a defined biological niche.

REC-4539 Enters the Clinic with a New LSD1 Scaffold

Recursion also dosed the first patient in a Phase I trial of REC-4539, its chemistry-derived LSD1 inhibitor, in April. The molecule was engineered with a reversible mechanism, shorter predicted half-life, and brain penetration to manage historical class risks such as thrombocytopenia, with initial safety and pharmacokinetics expected in the second half of 2027.

Platform Efficiency: Fewer Compounds, Faster Candidates

Management underscored platform efficiency, claiming roughly 90% fewer compounds synthesized per program versus industry norms, at around 330 on average compared with 2,500 to 5,000. Notable examples included advancing the RBM39 program from target identification to IND-enabling studies with about 200 compounds in roughly 18 months and bringing REC-4539 to the clinic in about 20 months with around 400 compounds.

ClinTech Capabilities Accelerate Trial Execution

The company pointed to its ClinTech tools as a differentiator in clinical development, reporting trial enrollment speeds about 30% to 60% faster in settings where the technology was deployed. These capabilities also widened eligibility in some studies, with the eligible patient pool rising from roughly 10% to about 40%, which could improve both trial efficiency and the odds of detecting meaningful signals.

Scaling a Data-Rich Discovery Platform

Recursion’s integrated platform now holds more than 50 petabytes of proprietary multimodal data and over 10 high-dimensional disease biology maps. Management said more than half of these maps were built in collaboration with Roche and Genentech, and highlighted internal transcriptomics models they claim outperform larger competitors, now being used for target discovery and patient stratification.

Partnership Momentum and Milestone Economics

Partner traction remained a bright spot, with cumulative inflows surpassing $500 million and 10 milestones delivered to date. During the quarter, Recursion recorded a fifth milestone from Sanofi tied to a potential first-in-class program, and several partner initiatives are approaching opt-in or development candidate decisions over the next 12 to 18 months.

Cost Discipline and Cash Runway Strengthen

Financially, the company emphasized tighter cost control, reporting a 30% year-over-year reduction in cash operating expenses. Recursion ended the quarter with $665 million in cash and equivalents, guiding that this provides funding into early 2028 and reiterating a 2026 cash operating expense target of under $390 million.

No Approved Drugs, Translation Risk Remains

Despite notable clinical progress, Recursion still has no approved, revenue-generating medicines, and future cash flows depend on successful registrational trials and partner decisions. Management acknowledged that the platform’s touted advantages in data and efficiency have yet to translate into repeatable product revenues or proven large-scale commercial outcomes.

Early Data, Regulatory Questions, and Safety Watchpoints

Executives stressed that many catalysts remain ahead, with fuller REC-1245 data and REC-4539 safety updates not expected for several years and additional REC-4881 details still pending. Regulatory pathways for first-in-disease indications and potential on-target toxicities, particularly as doses escalate and more patients are treated, were highlighted as key areas of ongoing risk.

Finite Runway Tied to Execution and Milestones

While the projected cash runway into early 2028 offers comfort, management noted that this horizon could compress if clinical timelines slip or partner milestones are delayed. Continued progress without new financing will rely heavily on hitting near-term data readouts, maintaining cost discipline, and securing additional partner contributions as programs mature.

Guidance: Multiple Readouts and Platform Leverage Ahead

Looking forward, Recursion guided to maintaining its sub-$390 million cash operating expense target for 2026 and reiterated that its $665 million cash pile should fund operations into early 2028. The company expects every clinical-stage program to generate multiple readouts over the next 12 to 18 months, while it continues to leverage its 50-plus petabytes of proprietary data, high-dimensional maps, and ClinTech tools to accelerate trials and support both wholly owned and partnered pipelines.

Recursion’s earnings call painted the picture of a high-velocity, data-centric drug developer that is beginning to validate its model but still sits early in the value-creation curve. Investors are being asked to weigh concrete proof-of-concept wins, improving efficiency, and rising partner confidence against the absence of near-term revenues and the execution risks that come with ambitious timelines and novel biology.